Lorence Kim is co-founder and managing partner at Ascenta Capital.
Previously, Lorence was a venture partner at Third Rock Ventures and the first chief financial officer of Moderna from 2014-2020, where he was responsible for raising $4.4 billion of capital for the company and deploying resources to discover and advance a pipeline of 24 development candidates across infectious disease, oncology, rare disease and autoimmune disease. Moderna raised, as of his departure, the three largest private financing rounds, the largest IPO and the largest follow-on offering in biotech history. Lorence joined Moderna after a 14-year investment banking career at Goldman Sachs as a managing director and co-head of the U.S. biotechnology investment banking effort. There, his responsibilities included corporate finance and mergers and acquisitions for the biotechnology industry, with several billion in equity and equity-linked financings, and more than $55 billion in M&A transactions. Lorence serves on the boards of directors of Flare Therapeutics, Cowen, Revolution Medicines and AmerisourceBergen. He is also on the board of governors of the American Red Cross. Previously, Lorence was a member of the board of directors of Seres Therapeutics.
Lorence holds an MBA in healthcare management as a Palmer Scholar from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania’s School of Medicine.